Fred Walder Joins Fluidigm as Chief Business Officer

Senior Executive from Fortune 500 Company to Lead Business Development and Marketing for Integrated Fluidic Circuit Inventor

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Fluidigm Corporation today announced Fred Walder has joined the company as its new Chief Business Officer. Walder joins Fluidigm after a long and celebrated career at a Fortune 500 company, Thermo Fisher Scientific, where he was most recently Senior Vice President, Customer and Commercial Excellence. Thermo Fisher is a $10+ billion (revenue) leader in the life sciences industry.

For Fluidigm, Walder will lead the company’s business functions to increase awareness and cement opportunities for Fluidigm integrated fluidic circuit-based technologies. Products based on these technologies bring unique capabilities to researchers working on single-cell gene expression, high-sample throughput genotyping and automated sample preparation and target enrichment for users of next generation sequencers.

“Fred brings a new level of business acumen to Fluidigm. His experience and wisdom will help us uncover fresh opportunities and drive Fluidigm’s growth to new heights,” said Gajus Worthington, president and chief executive officer of Fluidigm. “We have been seeking a person of unique capabilities to fill this position and just weren’t willing to compromise on someone who didn’t meet all of our needs. Fred exceeded those requirements and we believe we have strengthened our team significantly with his addition to Fluidigm.”

Fred Walder, Fluidigm's new Chief Business Officer said, "Fluidigm technology brings amazing new capabilities to life science fields such as single-cell gene expression and stem cell research. I believe integrated fluidic circuit technology is the real deal. It provides a significant enabling tool for understanding much more about how cells work."

Walder’s career began as an Engineering and Scientific Associate at Sandia National laboratories in 1979. A few years later he joined Nicolet Instrument Corporation where he spent 10 years in a variety of technical and management positions. In Thermo Fisher, one of the largest companies in the life science industry, Walder held various senior operating roles including president of several operating divisions. In his most recent position, Walder served as a corporate officer and Senior Vice President, Customer and Commercial Excellence reporting to Thermo Fisher’s Chief Executive Officer.

Walder received his Bachelor of Science in Chemistry from the University of Massachusetts. The University awarded Walder with their Career Achievement Award in 2008. He also completed the Technology Leadership Program at Stanford University’s Executive Institute, Graduate School of Business.

About Fluidigm

Fluidigm develops, manufactures and markets proprietary Integrated Fluidic Circuit (IFC) systems that significantly improve productivity in life science research. Fluidigm’s IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. These “integrated circuits for biology” are made possible by miniaturizing and integrating liquid handling components on a single microfluidic device. Fluidigm’s systems, consisting of instrumentation, software and chips, increase throughput, decrease costs and enhance sensitivity compared to conventional laboratory systems.

For more information, please visit www.fluidigm.com.

Fluidigm, the Fluidigm logo, BioMark, Access Array, Dynamic Array, Digital Array, FC1, Topaz, and NanoFlex are trademarks or registered trademarks of Fluidigm Corporation.



CONTACT:

Fluidigm Corporation
Howard High, 650-266-6081 (office)
510-786-7378 (mobile)
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Technology  Hardware  Nanotechnology  Health  Biotechnology  Other Health  Manufacturing  Engineering  Other Manufacturing  Natural Resources  Other Natural Resources  Research  Other Science  Science

MEDIA:

Logo
 Logo

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.